Literature DB >> 22054755

Polyclonal immunoglobulins and hyperimmune globulins in prevention and management of infectious diseases.

Jennifer L Hsu1, Nasia Safdar.   

Abstract

Immunoglobulin therapy has a rich history of use in preventing and treating infectious diseases; however, clinical data on the efficacy of immunoglobulin is lacking for many infectious diseases. Immunoglobulin therapy is routinely used in postexposure prophylaxis for bacterial infections, including tetanus, botulism, and diphtheria, and viral infections, including hepatitis A and B and varicella. Immunoglobulin therapy has also been used in many severe and life-threatening infections where treatments are limited, including toxic shock syndrome, respiratory syncytial virus infection, and cytomegalovirus infection. The authors review the evidence for the use of immunoglobulin therapy in common adult infectious diseases. Copyright Â
© 2011. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22054755     DOI: 10.1016/j.idc.2011.07.005

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN: 0891-5520            Impact factor:   5.982


  20 in total

1.  Assessment of panobacumab as adjunctive immunotherapy for the treatment of nosocomial Pseudomonas aeruginosa pneumonia.

Authors:  Y-A Que; H Lazar; M Wolff; B François; P-F Laterre; E Mercier; J Garbino; J-L Pagani; J-P Revelly; E Mus; A Perez; M Tamm; J-J Rouby; Q Lu; J Chastre; P Eggimann
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-05-24       Impact factor: 3.267

2.  Impact of Antibodies and Strain Polymorphisms on Cytomegalovirus Entry and Spread in Fibroblasts and Epithelial Cells.

Authors:  Xiaohong Cui; Daniel C Freed; Dai Wang; Ping Qiu; Fengsheng Li; Tong-Ming Fu; Lawrence M Kauvar; Michael A McVoy
Journal:  J Virol       Date:  2017-06-09       Impact factor: 5.103

3.  Effectiveness of hepatitis A vaccination as post-exposure prophylaxis.

Authors:  Ignasi Parrón; Caritat Planas; Pere Godoy; Sandra Manzanares-Laya; Ana Martínez; Maria Rosa Sala; Sofia Minguell; Nuria Torner; Mireia Jané; Angela Domínguez
Journal:  Hum Vaccin Immunother       Date:  2016-12-07       Impact factor: 3.452

4.  The K1 capsular polysaccharide from Acinetobacter baumannii is a potential therapeutic target via passive immunization.

Authors:  Thomas A Russo; Janet M Beanan; Ruth Olson; Ulrike MacDonald; Andrew D Cox; Frank St Michael; Evgeny V Vinogradov; Brad Spellberg; Nicole R Luke-Marshall; Anthony A Campagnari
Journal:  Infect Immun       Date:  2013-01-07       Impact factor: 3.441

5.  Human monoclonal antibody MBL-HCV1 delays HCV viral rebound following liver transplantation: a randomized controlled study.

Authors:  R T Chung; F D Gordon; M P Curry; T D Schiano; S Emre; K Corey; J F Markmann; M Hertl; J J Pomposelli; E A Pomfret; S Florman; M Schilsky; T J Broering; R W Finberg; G Szabo; P D Zamore; U Khettry; G J Babcock; D M Ambrosino; B Leav; M Leney; H L Smith; D C Molrine
Journal:  Am J Transplant       Date:  2013-01-28       Impact factor: 8.086

6.  Antibody inhibition of human cytomegalovirus spread in epithelial cell cultures.

Authors:  Xiaohong Cui; Ronzo Lee; Stuart P Adler; Michael A McVoy
Journal:  J Virol Methods       Date:  2013-05-10       Impact factor: 2.014

Review 7.  The establishment of surrogates and correlates of protection: Useful tools for the licensure of effective influenza vaccines?

Authors:  Brian J Ward; Stephane Pillet; Nathalie Charland; Sonia Trepanier; Julie Couillard; Nathalie Landry
Journal:  Hum Vaccin Immunother       Date:  2018-01-16       Impact factor: 3.452

Review 8.  Clinical development of monoclonal antibody-based drugs in HIV and HCV diseases.

Authors:  Michela Flego; Alessandro Ascione; Maurizio Cianfriglia; Stefano Vella
Journal:  BMC Med       Date:  2013-01-04       Impact factor: 8.775

9.  Reversing Autoimmunity Combination of Rituximab and Intravenous Immunoglobulin.

Authors:  A Razzaque Ahmed; Srinivas Kaveri
Journal:  Front Immunol       Date:  2018-07-18       Impact factor: 7.561

10.  The Use of Ebola Convalescent Plasma to Treat Ebola Virus Disease in Resource-Constrained Settings: A Perspective From the Field.

Authors:  Johan van Griensven; Anja De Weiggheleire; Alexandre Delamou; Peter G Smith; Tansy Edwards; Philippe Vandekerckhove; Elhadj Ibrahima Bah; Robert Colebunders; Isola Herve; Catherine Lazaygues; Nyankoye Haba; Lutgarde Lynen
Journal:  Clin Infect Dis       Date:  2015-08-10       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.